MRI-guided Lateral Lymph Node Dissection in Rectal Cancer

NCT04850027 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 268

Last updated 2021-04-26

No results posted yet for this study

Summary

To investigate the oncological outcome of lateral lymph node dissection in low rectal cancer based on MRI

Conditions

Interventions

PROCEDURE

TME+Lateral lymph node dissection.

TME and lateral lymph node dissection is performed in rectal cancer patients with lateral lymph node short diameter ≥ 5 mm.

Sponsors & Collaborators

  • Shengjing Hospital

    collaborator OTHER
  • Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

    collaborator OTHER
  • West China Hospital

    collaborator OTHER
  • The First Affiliated Hospital of Dalian Medical University

    collaborator OTHER
  • China-Japan Friendship Hospital

    collaborator OTHER
  • Peking University First Hospital

    collaborator OTHER
  • Beijing Friendship Hospital

    collaborator OTHER
  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    collaborator OTHER
  • Peking University Cancer Hospital & Institute

    collaborator OTHER
  • The First Hospital of Jilin University

    collaborator OTHER
  • China-Japan Union Hospital, Jilin University

    collaborator OTHER
  • Tianjin People's Hospital

    collaborator OTHER
  • Second Affiliated Hospital of Suzhou University

    collaborator OTHER
  • Peking Union Medical College Hospital

    collaborator OTHER
  • Ruijin Hospital

    collaborator OTHER
  • First Hospital of China Medical University

    collaborator OTHER
  • Chinese PLA General Hospital

    collaborator OTHER
  • Zhejiang Cancer Hospital

    collaborator OTHER
  • The Affiliated Hospital of Xuzhou Medical University

    collaborator OTHER
  • The Affiliated Hospital of Qingdao University

    collaborator OTHER
  • Shanghai Cancer Hospital, China

    collaborator OTHER
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Qian Liu, M.D. · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2022-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04850027 on ClinicalTrials.gov